ZA877132B - Drug compositions stabilized against oxidation - Google Patents

Drug compositions stabilized against oxidation

Info

Publication number
ZA877132B
ZA877132B ZA877132A ZA877132A ZA877132B ZA 877132 B ZA877132 B ZA 877132B ZA 877132 A ZA877132 A ZA 877132A ZA 877132 A ZA877132 A ZA 877132A ZA 877132 B ZA877132 B ZA 877132B
Authority
ZA
South Africa
Prior art keywords
against oxidation
stabilized against
drug compositions
compositions stabilized
oxidation
Prior art date
Application number
ZA877132A
Other languages
English (en)
Inventor
Kuchi Sury Murthy
Michael Ray Harris
Gerard Clifford Hokanson
Robert George Reisch Jr
Mahdi Bakir Fawzi
Frank Stanley Waldman
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25445868&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA877132(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of ZA877132B publication Critical patent/ZA877132B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ZA877132A 1986-10-20 1987-09-22 Drug compositions stabilized against oxidation ZA877132B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/921,717 US4830853A (en) 1986-10-20 1986-10-20 Drug compositions stabilized against oxidation

Publications (1)

Publication Number Publication Date
ZA877132B true ZA877132B (en) 1989-04-26

Family

ID=25445868

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA877132A ZA877132B (en) 1986-10-20 1987-09-22 Drug compositions stabilized against oxidation

Country Status (20)

Country Link
US (1) US4830853A (xx)
EP (1) EP0264887B1 (xx)
JP (1) JP2703906B2 (xx)
KR (1) KR960000430B1 (xx)
AT (1) ATE67090T1 (xx)
AU (1) AU604061B2 (xx)
CA (1) CA1297024C (xx)
DE (1) DE3772924D1 (xx)
DK (1) DK174916B1 (xx)
ES (1) ES2040726T3 (xx)
FI (1) FI100091B (xx)
GR (1) GR3002698T3 (xx)
HK (1) HK85694A (xx)
IE (1) IE60773B1 (xx)
NO (1) NO874352L (xx)
NZ (1) NZ221954A (xx)
PH (1) PH25582A (xx)
PT (1) PT85942B (xx)
SG (1) SG95494G (xx)
ZA (1) ZA877132B (xx)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL88502A (en) * 1987-12-14 1993-04-04 Squibb & Sons Inc Pharmaceutical compositions containing an angiotensin converting enzyme inhibitor
DE3942145A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh T-pa-solubilisierung
US5366730A (en) * 1989-12-20 1994-11-22 Boehringer Mannheim Gmbh Stabilized compositions having human tissue type plasminogen activator enzymatic activity
US6300361B1 (en) * 1990-07-25 2001-10-09 Novartis Ag Stabilized pharmaceutical compositions comprising acid donors
HU222489B1 (hu) * 1990-07-25 2003-07-28 Novartis Ag. Stabilizált gyógyszerkészítmények és eljárás az előállításukra
SI9111842A (sl) * 1991-11-25 1998-04-30 Krka Stabilna formulacija soli enalaprila, postopek za njeno pripravo in njena uporaba
US6296871B1 (en) * 1998-04-12 2001-10-02 Ranbaxy Laboratories Limited Stable solid pharmaceutical compositions containing enalapril maleate
PT1121103E (pt) * 1998-05-18 2007-02-28 Takeda Pharmaceutical Comprimidos de desintegração oral compreendendo um benzimidazole
TR200003600T2 (tr) 1998-06-05 2001-04-20 Warner-Lambert Company ACE inhibitörleri içeren bileşimlerin magnezyum oksit kullanılarak sabitlenmesi
NZ333206A (en) 1998-12-08 2000-07-28 Bernard Charles Sherman Solid pharmaceutical compositions comprising a stable magnesium salt of quinapril that acts as a ACE (Angiotensin Converting Enzyme) inhibitor
US6555551B1 (en) * 1999-08-31 2003-04-29 Mutual Pharmaceutical Co., Inc. Stable formulations of ACE inhibitors, and methods for preparation thereof
US20030225124A1 (en) * 1999-08-31 2003-12-04 Spiridon Spireas Stable formulations of ACE inhibitors, and methods for preparation thereof
US20040157911A1 (en) * 1999-08-31 2004-08-12 Spiridon Spireas Storage-stable and bio-stable formulations of ace inhibitors, and methods for preparation thereof
US20050202081A1 (en) * 2002-01-15 2005-09-15 Deepak Bahl Stable pharmaceutical compositions comprising ace inhibitor(s)
US20050069586A1 (en) * 2003-06-26 2005-03-31 Julia Hrakovsky Stable pharmaceutical compositions of 2-aza-bicyclo [3.3.0]-octane-3-carboxylic acid derivatives
US6869963B2 (en) * 2003-07-11 2005-03-22 Sandoz Ag Stable pharmaceutical compositions containing an ACE inhibitor
EP1694308A1 (en) * 2003-10-30 2006-08-30 Lupin Ltd. Stable formulations of ace inhibitors and methods for preparation thereof
GB2394660A (en) * 2003-12-17 2004-05-05 Niche Generics Ltd Stabilisation of pharmaceutical compositions comprising ACE inhibitor by absence of acidic excipients having large specific surface area, eg silicon dioxide
EA011862B1 (ru) * 2004-03-24 2009-06-30 Актавис Груп Хф. Композиции рамиприла
GB0518129D0 (en) * 2005-09-06 2005-10-12 Arrow Int Ltd Ramipril formulation
GB2431579A (en) * 2005-10-28 2007-05-02 Arrow Int Ltd Ramipril formulations
US20070098782A1 (en) * 2005-10-28 2007-05-03 Selamine Limited Ramipril Formulation
US9101160B2 (en) 2005-11-23 2015-08-11 The Coca-Cola Company Condiments with high-potency sweetener
US20070232680A1 (en) * 2006-04-04 2007-10-04 Vijayabhaskar Bolugoddu Preparation of ramipril and stable pharmaceutical compositions
JP2009533461A (ja) * 2006-04-19 2009-09-17 テバ ファーマシューティカル インダストリーズ リミティド ２−アザ−ビシクロ［３．３．０］−オクタン−３−カルボン酸誘導体の安定な医薬組成物
US8017168B2 (en) * 2006-11-02 2011-09-13 The Coca-Cola Company High-potency sweetener composition with rubisco protein, rubiscolin, rubiscolin derivatives, ace inhibitory peptides, and combinations thereof, and compositions sweetened therewith
GB0624090D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amine salts
GB0624084D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amino acid salts
GB0624087D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril combination salt
KR100808132B1 (ko) 2007-03-02 2008-02-29 고천일 음식물쓰레기 소멸처리장치
ES2364011B1 (es) 2009-11-20 2013-01-24 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
WO2012085249A2 (en) * 2010-12-24 2012-06-28 Krka, D.D., Novo Mesto Homogenous pharmaceutical oral dosage forms comprising lercanidipine and enalapril or their pharmaceutically acceptable salts
US8568747B1 (en) 2012-10-05 2013-10-29 Silvergate Pharmaceuticals, Inc. Enalapril compositions
SMT201900031T1 (it) 2014-07-31 2019-02-28 Pharmathen Sa Composizione di film orosolubile comprendente enalapril per il trattamento di ipertensione in una popolazione pediatrica
US9463183B1 (en) 2015-10-30 2016-10-11 Silvergate Pharmaceuticals, Inc. Lisinopril formulations
US20180325813A1 (en) 2015-11-07 2018-11-15 Ftf Pharma Private Limited Oral solution of ace inhibitors
US9669008B1 (en) 2016-03-18 2017-06-06 Silvergate Pharmaceuticals, Inc. Enalapril formulations
KR20200108023A (ko) 2018-01-11 2020-09-16 메리테이지 파마, 인크. 안정한 코르티코스테로이드 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE569430A (xx) * 1957-07-17
US3697641A (en) * 1970-01-02 1972-10-10 Gerhard W Ahrens Nonhygroscopic non-sugarbase noncariogenic-vitamin c releasable base material for use in the preparation of suckable tablets,lozenges and chocolate
ATE22530T1 (de) * 1980-07-29 1986-10-15 Sanofi Sa Durch saeure stabilisierte mischungen von thienopyridinderivaten und verfahren zum verhindern der zersetzung solcher verbindungen.
US4344949A (en) * 1980-10-03 1982-08-17 Warner-Lambert Company Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids
US4442089A (en) * 1982-07-06 1984-04-10 E. R. Squibb & Sons, Inc. Method for treating glaucoma with topical or systemic ACE inhibitor compositions
US4499079A (en) * 1982-11-18 1985-02-12 E. R. Squibb & Sons, Inc. Carboxy and substituted carboxy alkanoyl and cycloalkanoyl peptides
US4666705A (en) * 1985-06-03 1987-05-19 E. R. Squibb & Sons, Inc. Controlled release formulation
US4656188A (en) * 1985-10-09 1987-04-07 Merck & Co., Inc. Ace inhibitors in macular degeneration

Also Published As

Publication number Publication date
DK174916B1 (da) 2004-02-23
JPS63104931A (ja) 1988-05-10
CA1297024C (en) 1992-03-10
FI100091B (fi) 1997-09-30
PT85942A (en) 1987-11-01
KR960000430B1 (ko) 1996-01-06
DE3772924D1 (de) 1991-10-17
US4830853A (en) 1989-05-16
DK543587A (da) 1988-04-21
GR3002698T3 (en) 1993-01-25
PH25582A (en) 1991-08-08
NZ221954A (en) 1990-03-27
IE60773B1 (en) 1994-08-10
PT85942B (pt) 1990-07-31
SG95494G (en) 1994-10-28
NO874352D0 (no) 1987-10-19
EP0264887A1 (en) 1988-04-27
JP2703906B2 (ja) 1998-01-26
DK543587D0 (da) 1987-10-16
FI874594A0 (fi) 1987-10-19
FI874594A (fi) 1988-04-21
IE872550L (en) 1988-04-20
AU7939787A (en) 1988-04-21
ATE67090T1 (de) 1991-09-15
KR880004811A (ko) 1988-06-27
NO874352L (no) 1988-04-21
EP0264887B1 (en) 1991-09-11
AU604061B2 (en) 1990-12-06
ES2040726T3 (es) 1993-11-01
HK85694A (en) 1994-08-26

Similar Documents

Publication Publication Date Title
PT85942A (en) Drug compositions stabilized against oxidation
GR3002454T3 (en) Stabilized drug compositions
ZA88382B (en) Stabilized compositions
GR3021420T3 (en) 2-Substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ace
EP0562049A4 (en) Novel 4-arylpiperazines and 4-arylpiperidines
NZ223293A (en) Beta-alkyl melatonins and pharmaceutical compositions
GR3007465T3 (xx)
AU591525B2 (en) Stabilization of interferons